Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Lisa Zaba MD, PhD

Lisa C. Zaba MD, PhD

Clinical Associate Professor, Department of Dermatology, Stanford University, Palo Alto, California; Director, Stanford Multidisciplinary Merkel Cell Carcinoma Clinic; Director, Supportive Oncodermatology, Stanford South Bay Cancer Center, San Jose, California

Dr. Lisa Zaba is a Clinical Associate Professor in the Department of Dermatology and works at the Stanford Cancer Centers in Palo Alto and South Bay. 

She grew up in Salt Lake City, Utah, attended Stanford University and then obtained an MD and PhD at Cornell and the Rockefeller University, respectively. Her love of inflammatory skin conditions was developed during her PhD training studying psoriasis and figuring out the underlying pathways for this disease that led to the development of targeted biologic medications for psoriasis. The love of taking care of patients with cancer began during her internship at Memorial Sloan Kettering and continued on through dermatology residency at Stanford.

She established a multi-disciplinary Merkel cell carcinoma clinic at Stanford in 2018, and currently leads a clinical and basic science research team studying this disease, as well as a multicenter Merkel cell consortium.  The first line treatment for metastatic Merkel cell carcinoma is immune-checkpoint inhibition, and she also studies immune-related adverse events (irAEs) from these medications.

Dr. Zaba is dedicated to translational study of Merkel cell cancer and the intersection of cancer and immunology, and feels very grateful to her patients and colleagues for their collaboration, as we strive to improve the lives of patients with cancer. 


Dr. Zaba has no relevant disclosures.

Recent Contributions to PracticeUpdate:

  1. Mohs Surgery Monotherapy for Early-Stage Merkel Cell Carcinoma